Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

biohaven - BHVN

BHVN

Close Chg Chg %
28.38 -0.73 -2.57%

Closed Market

27.65

-0.73 (2.57%)

Volume: 1.09M

Last Updated:

Mar 28, 2025, 3:59 PM EDT

Trade Now

Company Overview: biohaven - BHVN

BHVN Key Data

Open

$28.30

 Day Range

26.57 - 28.30

52 Week Range

26.57 - 55.69

 Market Cap

$2.90B

Shares Outstanding

102.07M

 Public Float

89.15M

Beta

3.91

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$9.39

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.17M

  

BHVN Performance

1 Week
 
 -3.12%
 
1 Month
 
 -25.63%
 
3 Months
 
 -24.58%
 
1 Year
 
 -49.44%
 
5 Years
 
 -21.63%
 

BHVN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About biohaven - BHVN

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

BHVN At a Glance

Biohaven Ltd.
215 Church Street
New Haven, Connecticut 06510
Phone 1-203-404-0410 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -846,422,000.00
Sector Health Technology Employees 256
Fiscal Year-end 12 / 2025
View SEC Filings

BHVN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 8.928
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.357
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.012

BHVN Efficiency

Revenue/Employee N/A
Income Per Employee -3,306,335.938
Receivables Turnover N/A
Total Asset Turnover N/A

BHVN Liquidity

Current Ratio 3.491
Quick Ratio 3.491
Cash Ratio 3.153

BHVN Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -150.032
Return on Equity -198.828
Return on Total Capital -183.997
Return on Invested Capital -185.667

BHVN Capital Structure

Total Debt to Total Equity 8.64
Total Debt to Total Capital 7.953
Total Debt to Total Assets 5.948
Long-Term Debt to Equity 7.742
Long-Term Debt to Total Capital 7.126
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biohaven - BHVN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
1.39M 1.39M 3.37M 3.92M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.39M 1.39M 3.37M 3.92M
Depreciation
673.00K 1.36M 3.37M 3.92M
Amortization of Intangibles
- - 720.00K 25.00K
-
COGS Growth
+1,834.72% -0.50% +143.07% +16.44%
Gross Income
(1.39M) (1.39M) (3.37M) (3.92M)
Gross Income Growth
-1,834.72% +0.50% -143.07% -16.44%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
217.51M 566.55M 432.68M 881.19M
Research & Development
181.49M 437.07M 373.28M 795.87M
Other SG&A
36.02M 129.47M 59.40M 85.32M
SGA Growth
+90.07% +160.47% -23.63% +103.66%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(218.90M) (567.93M) (436.05M) (885.11M)
Non Operating Income/Expense
6.47M (1.91M) 26.50M 39.42M
Non-Operating Interest Income
- - 17.73M 21.33M
-
Equity in Earnings of Affiliates
- - - 5.26M
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(212.43M) (569.84M) (409.55M) (845.69M)
Pretax Income Growth
-79.01% -168.25% +28.13% -106.49%
Pretax Margin
- - - -
-
Income Tax
1.37M 438.00K (1.38M) 735.00K
Income Tax - Current - Domestic
- - 1.37M 438.00K
-
Income Tax - Current - Foreign
- - (1.38M) 735.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - 5.26M
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(213.80M) (570.28M) (408.17M) (846.42M)
Minority Interest Expense
- - - -
-
Net Income
(213.80M) (570.28M) (408.17M) (846.42M)
Net Income Growth
-80.16% -166.74% +28.43% -107.37%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(213.80M) (570.28M) (408.17M) (846.42M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(213.80M) (570.28M) (408.17M) (846.42M)
EPS (Basic)
-3.321 -8.363 -5.7326 -9.2774
EPS (Basic) Growth
-80.16% -151.82% +31.45% -61.84%
Basic Shares Outstanding
64.38M 68.19M 71.20M 91.23M
EPS (Diluted)
-3.321 -8.363 -5.7326 -9.2774
EPS (Diluted) Growth
-80.16% -151.82% +31.45% -61.84%
Diluted Shares Outstanding
64.38M 68.19M 71.20M 91.23M
EBITDA
(217.51M) (566.55M) (432.68M) (881.19M)
EBITDA Growth
-90.07% -160.47% +23.63% -103.66%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 61.077
Number of Ratings 16 Current Quarters Estimate -1.698
FY Report Date 03 / 2025 Current Year's Estimate -6.826
Last Quarter’s Earnings -1.85 Median PE on CY Estimate N/A
Year Ago Earnings -9.28 Next Fiscal Year Estimate -5.83
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 16 14
Mean Estimate -1.70 -1.88 -6.83 -5.83
High Estimates -1.26 -1.28 -5.00 -3.93
Low Estimate -2.03 -3.77 -9.63 -9.19
Coefficient of Variance -13.75 -31.71 -16.01 -21.98

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 13
OVERWEIGHT 2 2 2
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Biohaven - BHVN

Date Name Shares Transaction Value
Mar 6, 2025 John Winston Childs Director 73,170 Open market or private purchase of non-derivative security Non-derivative transaction at $41 per share 2,999,970.00
Mar 6, 2025 John Winston Childs Director 24,452 Open market or private purchase of non-derivative security Non-derivative transaction at $30.73 per share 751,409.96
Mar 6, 2025 John Winston Childs Director 76,570 Open market or private purchase of non-derivative security Non-derivative transaction at $30.73 per share 2,352,996.10
Mar 6, 2025 John Winston Childs Director 25,291 Open market or private purchase of non-derivative security Non-derivative transaction at $30.73 per share 777,192.43
Jun 20, 2024 Bruce D. Car Chief Scientific Officer 30,000 Open market or private purchase of non-derivative security Non-derivative transaction at $33.58 per share 1,007,400.00
May 15, 2024 Gregory H. Bailey Director 1,615,071 Open market or private purchase of non-derivative security Non-derivative transaction at $34.19 per share 55,219,277.49
May 3, 2024 Robert J. Hugin Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Julia Paige Gregory Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Michael Thomas Heffernan Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Kishan C. Mehta Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Irina Antonijevic Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 23, 2024 Vladimir Coric Chief Executive Officer; Director 1,788,417 Open market or private purchase of non-derivative security Non-derivative transaction at $41 per share 73,325,097.00
Apr 8, 2024 Vladimir Coric Chief Executive Officer; Director 840,890 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2024 Vladimir Coric Chief Executive Officer; Director 407,213 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Biohaven in the News